Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
Peter J GoadsbyAndrew M BlumenfeldRichard B LiptonDavid W DodickKavita KalidasAubrey M AdamsAbhijeet JakateChengcheng LiuArmin SzegediJoel M TrugmanPublished in: Cephalalgia : an international journal of headache (2020)
Evaluation of the time course of effect of ubrogepant showed pain relief as the most sensitive and earliest measure of clinical effect, followed by absence of most bothersome symptom, and pain freedom. Efficacy was demonstrated out to 48 h, providing evidence of the long-lasting effect of ubrogepant. This evaluation supports the role of examining the entire time course of effect to understand fully the utility of an acute treatment for migraine.Trial registration: ACHIEVE I (ClinicalTrials.gov, NCT02828020) and ACHIEVE II (ClinicalTrials.gov, NCT02867709).